Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488548 · ClinicalTrials.gov registry record · Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis, sponsored by Epigenetix.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 6
- Study locations
NCT05488548: Recruiting Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis, sponsored by Epigenetix.
NCT05488548 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis that is actively recruiting participants, run by Epigenetix. The registered enrollment target is 75 participants, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (15% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05488548, a Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis, is actively recruiting participants, sponsored by Epigenetix.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Primary Outcome
MTD is the highest dose level at which ≤30% of patients experienced DLTs during cycle 1.
Conditions Studied
Interventions
- DRUG EP31670
Study Locations (6)
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- University of Washington/Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
What NCT05488548 shows while recruiting
NCT05488548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (15% lower).
The record links to 4 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which EP31670 is the first listed.
NCT05488548 lists 6 locations in 6 states (Arizona, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05488548 about?
NCT05488548 is a clinical study titled "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies". A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
What is the current status of trial NCT05488548?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-12-21. Estimated completion is 2025-05.
What conditions does trial NCT05488548 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Myelofibrosis, Castrate Resistant Prostate Cancer, NUT Carcinoma.
What interventions are being tested in trial NCT05488548?
The interventions under investigation include: EP31670 (DRUG).
Who is sponsoring clinical trial NCT05488548?
This trial is sponsored by Epigenetix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05488548 being conducted?
This trial has 6 study locations across Arizona, Florida, Massachusetts, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05488548's enrollment target sits among peer trials
75 22nd of 73 higher than 51 of 73 other Chronic Myelomonocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelomonocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI